Recombinant Human sRANK Receptor/TNFRSF11A (Recombinant Human soluble Receptor Activator of Nuclear Factor kappa-B Receptor; rHusRANK Receptor)；重组人可溶性核因子κB受体激活剂/TNFRSF11A
Synonyms
CD265; ODFR; TNFRSF11A; TRANCE R; CD265; CD265 antigen; FEO; loss of heterozygosity, 18, chromosomal region 1; ODFROSTS; OFE; OPTB7; Osteoclast differentiation factor receptor; PDB2; RANKLOH18CR1; Receptor activator of NF-KB; receptor activator of nuclear factor-kappa B; TRANCER; tumor necrosis factor receptor superfamily member 11A; tumor necrosis factor receptor superfamily, member 11a, activator of NFKB; tumor necrosis factor receptor superfamily, member 11a, NFKB activator
Purity
>98% by SDS-PAGE and HPLC analyses.
Biological Activity
Fully biologically active when compared to standard. The ED50 as determined by its ability to inhibit sRANK Ligand induced nuclear factor kappa B(NFkappaB) in RAW 264.7 cells is less than 50ng/ml, corresponding to a specific activity of >2.0×104IU/mg in the presence of 15ng/ml of recombinant sRANK Ligand.
Physical Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation
Lyophilized from a 0.2μm filtered concentrated solution in 20mM Tris-HCl, pH8.0, 150mM NaCl.
Endotoxin
Less than 0.1EU/μg of rHusRANK Receptor as determined by LAL method.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤-20℃. Further dilutions should be made in appropriate buffered solutions.
Category
Cytokine
Background
RANK Ligand and RANK Receptor are members of the TNF superfamily that play an important role in the regulation of specific immunity and bone turnover. RANK Receptor was originally identified as a dendritic-cell-membrane protein, which by interacting with RANKL augments the ability of dendritic cells to stimulate naïve T cell proliferation and to promote the survival of RANK + T cells. RANK is also expressed in a variety of tissues including skeletal muscle, thymus, liver, colon, small intestine and adrenal gland. The RANK/RANKL interaction is important in the regulation of osteoclastogenesis and in dendritic-cellmediated T cell immune responses. Impairments in RANK signaling have been implicated in the induction of expansile osteolysis and Paget disease of bone (PDB2). Recombinant human sRANK receptor is a 19.1kDa polypeptide containing the TNFR homologous cysteine rich portion of the extracellular domain of RANK receptor (174 amino acid residues).
